Relevant bibliographies by topics / Antifungal drugs

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Antifungal drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antifungal drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antifungal drugs"

1

Cross, J. T., S. L. Hickerson, and T. Yamauchi. "Antifungal Drugs." Pediatrics in Review 16, no. 4 (April 1, 1995): 123–29. http://dx.doi.org/10.1542/pir.16-4-123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cross, J. Thomas, Steven L. Hickerson, and Terry Yamauchi. "Antifungal Drugs." Pediatrics In Review 16, no. 4 (April 1, 1995): 123–29. http://dx.doi.org/10.1542/pir.16.4.123.

Full text
Abstract:
Introduction Fungi have been recognized as pathogens for many years. However, the incidence of fungal infections in the pediatric population has increased substantially due to the increased use of broad-spectrum antibiotics, immunosuppressive agents, hyperalimentation products, and central venous catheters in addition to the acquired immunodeficiency syndrome (AIDS) epidemic. The physician involved with the care of children should know the agents effective against these pathogens (Table 1). Amphotericin B has a long history of both efficacy and toxicity because it was the only available systemic agent for many years. With the introduction of ketoconazole, fluconazole, and itraconazole over the past decade, the decision of which agent to use has become much more difficult. Clinical trials are underway to help answer these questions, but until these are completed, the clinician must weigh the risks and benefits of therapy for each patient individually. Amphotericin B BACKGROUND Amphotericin B is entering its fourth decade as an antifungal agent. Since its introduction in the mid-1950s, it has been the cornerstone of management of systemic fungal infections. Even with the introduction of the azoles, it continues to be the treatment of choice for many conditions. CHEMISTRY, MECHANISM OF ACTION Streptomyces nodosus, a soil actinomycete, is the source of the amphotericins A and B. Amphotericin B is the commercially available product, and it may contain a small amount (<5%) of amphotericin A.
APA, Harvard, Vancouver, ISO, and other styles
3

Houšť, Jiří, Jaroslav Spížek, and Vladimír Havlíček. "Antifungal Drugs." Metabolites 10, no. 3 (March 12, 2020): 106. http://dx.doi.org/10.3390/metabo10030106.

Full text
Abstract:
We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-β-d-glucan synthase, lanosterol 14-α-demethylase, protein, and deoxyribonucleic acid biosynthesis, or sequestrate ergosterol. Their most severe side effects are hepatotoxicity, nephrotoxicity, and myelotoxicity. Whereas triazoles exhibit the most significant drug–drug interactions, echinocandins exhibit almost none. The antifungal resistance may be developed across most pathogens and includes drug target overexpression, efflux pump activation, and amino acid substitution. The experimental antifungal drugs in clinical trials are also reviewed. Siderophores in the Trojan horse approach or the application of siderophore biosynthesis enzyme inhibitors represent the most promising emerging antifungal therapies.
APA, Harvard, Vancouver, ISO, and other styles
4

Warnock, D. W. "Antifungal drugs." Current Opinion in Infectious Diseases 1, no. 3 (May 1988): 375–79. http://dx.doi.org/10.1097/00001432-198805000-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Warnock, D. W. "Antifungal drugs." Current Opinion in Infectious Diseases 2, no. 3 (June 1989): 362–66. http://dx.doi.org/10.1097/00001432-198906000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Warnock, David W. "Antifungal drugs." Current Opinion in Infectious Diseases 3, no. 6 (December 1990): 765–69. http://dx.doi.org/10.1097/00001432-199012000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Akkuş, İlknur, and Birgül Kaçmaz. "Antifungal drugs." Journal of Current Hematology & Oncology Research 1, no. 2 (May 29, 2023): 41–46. http://dx.doi.org/10.51271/jchor-0010.

Full text
Abstract:
Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978. The discovery of first-generation azoles (fluconazole and itraconazole) in the 1990s has created a new step in the treatment of fungi. In the years that followed, with the development of lipid formulations of amphotericin B, the introduction of second-generation azoles, and the release of the most recently developed class, echinocandins, the foundations of today’s existing antifungal classes were laid. This article is aimed to review the mechanism of action, side effects and clinical use indications of the main antifungal drugs used in the treatment of systemic fungal infections.
APA, Harvard, Vancouver, ISO, and other styles
8

Perfect, John R. "Molecular targets for new antifungal drugs." Canadian Journal of Botany 73, S1 (December 31, 1995): 1187–91. http://dx.doi.org/10.1139/b95-377.

Full text
Abstract:
Fungal infections in man and animals have a significant impact on health. However, there are only a few antifungal agents available for treatment of invasive mycoses. Further understanding of fungal molecular pathogenesis in collaboration with biochemistry and molecular modeling strategies should be able to develop new selective fungicidal agents. An example of this approach is Cryptococcus neoformans, which is reviewed in this discussion, as a model system for identification of antifungal molecular targets. Key words: antifungals, fungi, treatment, cryptococcosis, molecular biology, targets.
APA, Harvard, Vancouver, ISO, and other styles
9

Van Daele, Ruth, Isabel Spriet, Joost Wauters, Johan Maertens, Toine Mercier, Sam Van Hecke, and Roger Brüggemann. "Antifungal drugs: What brings the future?" Medical Mycology 57, Supplement_3 (June 1, 2019): S328—S343. http://dx.doi.org/10.1093/mmy/myz012.

Full text
Abstract:
AbstractThe high burden and growing prevalence of invasive fungal infections (IFIs), the toxicity and interactions associated with current antifungal drugs, as well as the increasing resistance, ask for the development of new antifungal drugs, preferably with a novel mode of action. Also, the availability of oral or once-weekly alternatives would enable ambulatory treatment resulting in an improved patient's comfort and therapy adherence. However, only one new azole and two new posaconazole-formulations were marketed over the last decade. This review focuses on the antifungal drugs in the pipeline undergoing clinical evaluation. First, the newest azole, isavuconazole, with its improved safety profile and reduction in DDIs, will be discussed. Moreover, there are two glucan synthase inhibitors (GSIs) in the antifungal pipeline: rezafungin (CD101), a long-acting echinocandin with an improved stability that enables once weekly administration, and SCY-078, an orally available GSI with efficacy against azole- and echinocandin resistant isolates. A new oral formulation of amphotericin B will also be presented. Moreover, the first representative of a new antifungal class, the orotomides, with a broad spectrum and no cross-resistance with current antifungal classes, will be discussed. Finally, an overview of other antifungals that are still in earlier clinical development phases, is provided.
APA, Harvard, Vancouver, ISO, and other styles
10

DiDomenico, Beth. "Novel antifungal drugs." Current Opinion in Microbiology 2, no. 5 (October 1999): 509–15. http://dx.doi.org/10.1016/s1369-5274(99)00009-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antifungal drugs"

1

Lai, Yu-Wen. "Transcriptomic analysis of synergy between antifungal drugs and iron chelators for alternative antifungal therapies." Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/17064.

Full text
Abstract:
There is an urgent need to improve the efficacy and range of antifungal drugs due to a global increase in invasive fungal infections, which are difficult to treat and are associated with high rates of mortality. Developing new drugs is expensive and time consuming and synergistic therapies that enhance the efficacy of current drugs are an alternative approach. Iron chelators have been used as antifungal synergents in salvage therapy, however, how these cause synergy are unknown. This thesis aims to use a transcriptomic approach to understand the mechanistic detail of antifungal-chelator synergy in the pathogen Cryptococcus to find potential antifungal targets. It focuses on amphotericin B (AMB) and lactoferrin (LF) synergy and voriconazole (VRC) and EDTA antagonism upon screening the interactions of various antifungal - chelator combinations in Cryptococcus. LF was found to enhance the antifungal effect of AMB in two ways: via the dysregulation of stress responses and metal homeostasis that disrupted the cell’s ability to mount an appropriate stress response, and by overwhelming the cell’s stress response via the cumulative strain from ER stress, disruption of transmembrane transport processes and increased metal dysregulation. Metal homeostasis was vital to both processes and the direct disruption of metal homeostasis, via deletion of iron (Aft1, Cir1 and HapX) and zinc (Zap1 and Zap104) regulating transcription factors, resulted in increased AMB susceptibility. Analysis of drug-binding domains in Zap1 and Zap104 found these to contain druggable sites and be potential antifungal drug targets. EDTA in the presence of VRC was found to disrupt mitochondrial functions along with an up-regulation of drug efflux genes, suggesting a potential mechanism of antagonism by mediating the efflux of intracellular VRC. Overall, metal regulation is important for resisting antifungal stress and is a potential antifungal strategy, where Zap1 is a potential antifungal drug target.
APA, Harvard, Vancouver, ISO, and other styles
2

Sabzevari, Omid. "Azole antifungal drugs and cytochrome P450 induction." Thesis, University of Surrey, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359878.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Venkateswarlu, Kanamarlapudi. "Azole antifungal drugs mode of action and resistance." Thesis, University of Sheffield, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Siau, Hong. "The effects of antifungal drugs in combination on the growth of Candida species." Thesis, University of Cambridge, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359415.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Johnson, E. M. "In vitro effects of antifungal drugs on Candida albicans and phagocytic cell function." Thesis, University of Bristol, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.375031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Abu-Elteen, Khalid Hussein. "Effect of sub-inhibitory concentrations of antifungal drugs on adherence of Candida species." Thesis, Loughborough University, 1991. https://dspace.lboro.ac.uk/2134/33210.

Full text
Abstract:
The adherence of three Candida species to human buccal epithelial cells (BECs) following treatment of the yeast with sub-inhibitory concentrations of amphotericin B, nystatin, miconazole nitrate, 5-fluorocytosine, octenidine and pirtenidine was investigated in vitro. Pre-incubation of C. albicans (two strains), C. tropicalis or C.kefyr with these antifungal drugs inhibited their adherence to varying degrees (reduction between 17% and 78% of the control value). Pre-treatment of yeast for a short period (l hr) had less effect on adhesion than pre-treatment for a long period (24 hr). Furthermore, treating C. albicans with a combination of amphotericin B plus 5-fluorocytosine, both at 1/8 MIC level, led to stronger adherence inhibition than that obtained for yeast pre-treated with either one alone at 1/4 MIC levels. In addition, the pre-treatment of either Candida or BECs or both types of cells with the drugs reduced adherence, the reduction being greatest when both types of cells were pre-treated. No difference in adherence between stationary or exponential phase yeast to BEC was observed and the drugs were effective in reducing the adherence of cells from either growth phase.
APA, Harvard, Vancouver, ISO, and other styles
7

Dahal, Gopal Prasad. "Development of Selective Inhibitors against Enzymes Involved in the Aspartate Biosynthetic Pathway for Antifungal Drug Development." University of Toledo / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1532889045486984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Silva, Hilris Rocha e. "Sistemas nanoestruturados estabilizados com álcool cetílico etoxilado e propoxilado contendo óleo de copaíba e fluconazol potencialmente ativo contra dermatomicoses /." Araraquara : [s.n.], 2011. http://hdl.handle.net/11449/102460.

Full text
Abstract:
Resumo: Nas últimas décadas, tem ocorrido um aumento expressivo na incidência de infecções fúngicas. Por outro lado, o tratamento das micoses nem sempre é efetivo, pois os fármacos antifúngicos disponíveis apresentam espectro de atividade e perfil farmacocinético inadequados, em especial no tratamento das lesões cutâneas. Portanto, o objetivo do presente trabalho foi desenvolver e caracterizar sistemas nanoestruturados estabilizados com álcool cetílico etoxilado 20 OE e propoxilado 5 OP (PROC) contendo fluconazol (FLU), empregando ácido oléico (AO) e óleo de copaíba como fases oleosas. A caracterização química, seguida de ensaios biológicos, dos óleos de copaíba de diferentes fontes, foi determinante para a escolha do óleo a ser usado no desenvolvimento das formulações. A construção de diagramas de fases com ambos os óleos mostrou que diferentes sistemas como microemulsões (ME) e cristais líquidos (CL) podem ser formados. A caracterização físico-química (MLP, SAXS e Reologia) mostrou que na região de 40% de PROC, o aumento da quantidade de água favorece a formação de sistemas mais estruturados como CL de fase lamelar e hexagonal quando se utiliza AO e óleo de copaíba... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: In the last decades, there has been an expressive increase in incidence of fungal infections. On the other hand, the treatment of mycoses is not always effective, because available antifungal drugs show inappropriate activity spectrum and pharmacokinetic profile. The aim of this work was to develop and characterize nanostructured systems stabilized by propoxyl (5OP) ethoxyl (20 OE) cethyl alcohol (PROC) containing fluconazole, using oleic acid and copaiba oil from different origins as oily phases. Chemical and biological characterization of copaiba oils from different origins was decisive for the choice of oil to be used in the development of the formulations. The construction of phase diagrams with studied copaiba oils showed that different systems such as microemulsions (ME) and liquid crystals (CL) can be formed. The characterization by polarized light microscopy, rheological behavior and SAXS confirmed the results obtained in phase diagrams, showing that in the region of 40% of PROC, the increase in the quantity of water favors the formation of more structured systems as CL of lamellar and hexagonal phase... (Complete abstract click electronic access below)
Orientador: Maria Palmira Daflon Gremião
Coorientador: Georgino Honorato de Oliveira
Banca: Nereide Stela Santos Magalhães
Banca: Marlus Chorilli
Banca: Silvia Stanisçuaski Guterres
Banca: Renata Fonseca Vianna Lopez
Doutor
APA, Harvard, Vancouver, ISO, and other styles
9

Голубнича, Вікторія Миколаївна, Виктория Николаевна Голубничая, Viktoriia Mykolaivna Holubnycha, Ann Masko, and Inna Zakorko. "Evaluation of the sensetiviti candida spp. isolated from pregnant women and newborns to antifungal drugs." Thesis, Видавництво СумДУ, 2010. http://essuir.sumdu.edu.ua/handle/123456789/6774.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ellepola, Arjuna Nishantha Bandara. "The post-antifungal effect (PAFE) and its impact on the pathogenic attributes of Candida albicans." Thesis, Hong Kong : University of Hong Kong, 1999. http://sunzi.lib.hku.hk/hkuto/record.jsp?B21253274.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antifungal drugs"

1

St, Georgiev Vassil, New York Academy of Sciences., and International Conference on Drug Research in Immunologic and Infectious Diseases (1st : 1987 : Garden City, N.Y.), eds. Antifungal drugs. New York, N.Y: New York Academy of Sciences, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fernandes, Prabhavathi B., ed. New Approaches for Antifungal Drugs. Boston, MA: Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4899-6729-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

B, Fernandes P., ed. New approaches for antifungal drugs. Boston: Birkhäuser, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Antifungal drugs: (1,3) [beta]-glucan synthase inhibitors. New York: Springer, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

International, Telesymposium on Recent Trends in the Discovery Development and Evaluation of Antifungal Agents (1987). Recent trends in the discovery, development and evaluation of antifungal agents: Proceedings of an international telesymposium, May 1987. Barcelona: J.R. Prous Science, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

A, Kucers, ed. The use of antibiotics: A clinical review of antibacterial, antifungal, and antiviral drugs. 5th ed. Oxford: Butterworth-Heinemann, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Grayson, M. Lindsay. Kucers' the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs : Antibiotics. London: Hodder Arnold, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krysan, Damian J., and W. Scott Moye-Rowley, eds. Antifungal Drug Resistance. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3155-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

1923-, Jacobs Paul H., and Nall Lexie 1932-, eds. Antifungal drug therapy: A complete guide for the practitioner. New York: M. Dekker, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1934-, Yamaguchi Hideyo, Kobayashi George S. 1927-, Takahashi Hisashi 1929-, and International Conference on Antifungal Chemotherapy (1st : 1990 : Oiso-machi, Japan), eds. Recent progress in antifungal chemotherapy. New York: Dekker, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antifungal drugs"

1

Hay, Roderick J. "Antifungal Drugs." In European Handbook of Dermatological Treatments, 1361–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-45139-7_132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hay, R. J. "Antifungal drugs." In European Handbook of Dermatological Treatments, 700–710. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-662-07131-1_122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bustamante, Beatriz, Jose A. Hidalgo, and Pablo E. Campos. "Antifungal Drugs." In Current Progress in Medical Mycology, 29–89. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-64113-3_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bhandari, Prasan. "Antifungal drugs." In Pharmacology Mind Maps for Medical Students and Allied Health Professionals, 600–611. Boca Raton, FL : CRC Press/Taylor & Francis, 2020.: CRC Press, 2019. http://dx.doi.org/10.1201/9780429023859-70.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Raj, Gerard Marshall. "Antifungal Drugs." In Introduction to Basics of Pharmacology and Toxicology, 905–26. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6009-9_57.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ryder, Neil S., and Hubert Mieth. "Allylamine Antifungal Drugs." In Current Topics in Medical Mycology, 158–88. New York, NY: Springer New York, 1992. http://dx.doi.org/10.1007/978-1-4612-2762-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sanglard, Dominique. "Resistance to Antifungal Drugs." In Essentials of Clinical Mycology, 135–51. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6640-7_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Graybill, John R. "Antifungal Drugs and Resistance." In Antimicrobial Resistance, 217–34. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4757-9203-4_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Joseph, Joveeta, and Savitri Sharma. "Antifungal Therapy in Eye Infections: New Drugs, New Trends." In Recent Trends in Antifungal Agents and Antifungal Therapy, 217–36. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2782-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Backer, Marianne D., Walter H. M. L. Luyten, and Hugo F. Bossche. "Antifungal Drug Discovery: Old Drugs, New Tools." In Pathogen Genomics, 167–96. Totowa, NJ: Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-172-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antifungal drugs"

1

Rodrigues da Silva, Abdênego, Fernanda Viana Cabral, Adriana Fontes, and Martha Ribeiro Simões. "Light-based antifungal strategy for the control of Candida auris." In Latin America Optics and Photonics Conference. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/laop.2022.w4a.58.

Full text
Abstract:
Candida auris is a pathogen that has been attracting worldwide focus due to its high resistance to conventional drugs. This work evaluated the photodynamic inactivation mediated by two phenothiazine dyes against the CBS 10913 strain.
APA, Harvard, Vancouver, ISO, and other styles
2

Hardhi, Matthew, Delfina, Putty Ekadewi, Retno Widyati, Yuswan Muharam, Widodo Wahyu Purwanto, Dewi Tristantini, and Misri Gozan. "Conceptual design of antifungal and antibacterial herbal ear hygiene product." In THE 5TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, AND MEDICAL DEVICES: Proceedings of the 5th International Symposium of Biomedical Engineering (ISBE) 2020. AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0047190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Montana, Fajar Daniswara, Yuni Setyaningsih, and Fajriati Zulfa. "Effectiveness of Cocoa (Theobroma Cacao L.) Seed Extract on the Growth of in Vitro Malassezia Furfur." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.05.01.

Full text
Abstract:
ABSTRACT Background: Pityriasis versicolor or Tinea versicolor is a skin disease caused by the Malassezia furfur which is often found in Indonesia. People can use anti-fungal drugs to treat this disease. However, long-term use of anti-fungal drugs is relatively more expensive and can have side effects for its users. Cocoa bean husk contains flavonoids, saponins, and alkaloids which have anti-fungal effects. This study aimed to determine the antifungal effectiveness of the cocoa bean husk extract on the growth of M. furfur. Subjects and Methods: This was an experimental study using cocoa bean husk extract with a concentration variance of 25%, 50%, 75%, 100%, with a positive control for ketoconazole 2% and a negative control using distilled water. The test was carried out by the well diffusion method using Sabouraud Dextrose Agar media. The inhibition of fungal growth was calculated by looking at the clear zone formed after 48 hours. Data were analyzed using Kruskal-Wallis and Post hoc Mann Whitney statistical tests. Results: The mean diameter of the inhibition zone at a concentration of 25%, 50%, 75% and 100% was 3.42 mm, 4.07 mm, 4.9 mm, and 7.3 mm, respectively, and it was statistically significant (p = 0.001). Conclusion: Cocoa bean husk extract has weak anti-fungal effectiveness at concentrations of 25%, 50%, and 75%, while at 100% it has moderate effectiveness. Keywords: antifungal, Pityriasis versicolor, cocoa bean shell, well diffusion, Malassezia furfur Correspondence: Yuni Setyaningsih. Department of Parasitology, Faculty of Medicine, Universitas Pembangunan Nasional “Veteran” Jakarta. DOI: https://doi.org/10.26911/the7thicph.05.01
APA, Harvard, Vancouver, ISO, and other styles
4

Maioto, Rita, Inês Ribeiro, Mariana Girão, Maria F. Carvalho, and Ana Sampaio. "Evaluation of Antifungal Activities of Actinobacterial Extracts Isolated from Deep-Sea Laminaria ochroleuca against Pathogenic Fungi." In The 2nd International Electronic Conference on Antibiotics—Drugs for Superbugs: Antibiotic Discovery, Modes of Action And Mechanisms of Resistance. Basel Switzerland: MDPI, 2022. http://dx.doi.org/10.3390/eca2022-12716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Milović, Emilija, Nenad Janković, Jelena Petronijević, and Nenad Joksimović. "CHEMICO-BIOLOGICAL INTERACTION OF SELECTED TETRAHYDROPYRIMIDINES." In 1st INTERNATIONAL Conference on Chemo and BioInformatics. Institute for Information Technologies, University of Kragujevac, 2021. http://dx.doi.org/10.46793/iccbi21.347m.

Full text
Abstract:
Tetrahydropyrimidines (THPMs) attracted attention as a very important class of aza heterocycles with broad pharmacological activities during the past years. In many studies have been proven that THPMs have anticancer, anti-inflammatory, antimicrobial, antioxidant, antifungal, anti-HIV activity. Bearing in mind our interest in medicinal and Biginelli chemistry, we investigated interaction with important biomacromolecules (DNA, BSA) and our earlier synthetized THPMs derivatives with proven very good cytotoxic activity.[1] Investigation of affinity of compounds A and B (Figure 1) to bind to bovine serum albumin (BSA) is based on the fact that the efficiency of drugs depends on their ability to bind for carrier protein. Binding properties were investigated by using the fluorescence emission titration of BSA with A and B. The obtained values of Ka, which are in optimum range which is considered to be 106-107M-1 indicate that both compounds have great ability to bind to BSA. In addition, Ka values for A-BSA and B-BSAshow that both compounds are suitable for drug-cell
APA, Harvard, Vancouver, ISO, and other styles
6

Uaraksakul, Pataraporn, and Pragatsawat Chanprapai. "In Vitro Antifungal Activity of Boesenbergia rotundo Linn. and Syzygium aromaticum L. Merr. and Perry Extracts against Aspergillus flavus." In The 2nd International Electronic Conference on Antibiotics—Drugs for Superbugs: Antibiotic Discovery, Modes of Action And Mechanisms of Resistance. Basel Switzerland: MDPI, 2022. http://dx.doi.org/10.3390/eca2022-12687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Park, Ju Ho, Hyesook Kim, and So Hee Kim. "Abstract 2327: Azole antifungal drugs induce cell death by suppressing mTOR through PI3K/Akt inhibition in human breast cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Adawiyah, Robiatul, Alifa Husnia AlHaq, Davita Kristabel Mandala, Muhammad Sahlan, Diah Kartika Pratami, and Siti Farida. "The effectivity of Indonesian propolis from Tetragonula biroi bee as an antifungal agent for Candida sp. and Cryptococcus neoformans." In THE 5TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, AND MEDICAL DEVICES: Proceedings of the 5th International Symposium of Biomedical Engineering (ISBE) 2020. AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0047205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tyrkov, Alexey, Svetlana Luzhnova, Evgenia Utyaganova, and Ekaterina Yurtayeva. "Promising materials based on Tetrahydro-[1,2,4]Oxadiazole[3,2-C][1,4]Oxazine for innovative biotechnologies." In "The Caspian in the Digital Age" within the framework of the International Scientific Forum "Caspian 2021: Ways of Sustainable Development". Dela Press Publishing House, 2022. http://dx.doi.org/10.56199/dpcsebm.sddh5085.

Full text
Abstract:
The synthesis of 2-[(1,3-diphenyl-1H-1,2,4-triazol-5-yl) dinitromethyl]-5,6,8,8a-tetrahydro-[1,2,4] oxadiazol[3,2-c][1,4] oxazine is caused by the reaction of morpholine interaction in the presence of hydrogen peroxide with 2-(1,3-diphenyl-1H-1,2,4-triazol-5-yl)-2,2-dinitroacetonitrile and sodium tungstate in a catalytic amount. The latter interacts with an excess of KOH in ethanol to form the potassium salt aci-5-dinitromethyl-1,3-diphenyl-1H-1,2,4-triazole and 5,6,8,8a-tetrahydro-[1,2,4] oxadiazole[3,2-c] [1,4] oxazine-2-ol. The ability of compounds 3-5 to inhibit the growth and development of museum strains of Staphylococcus aureus RP, E. coli O39, Pseudomonas aeruginosa 143 and clinical strain of Streptococcus pneumonia, as well as clinically significant species of fungi Trichophyton rubrum, Microsporumcanis and Candida albicans was investigated. It was revealed that the compounds have bacteriostatic activity against the studied bacterial strains: 3 and 4 expressed in a range of low concentrations. Compounds 3-5 demonstrate a fungistatic effect: compound 3 in a range of low concentrations. In relation to fungal strains, compounds 3-5 demonstrate a fungistatic effect: compound 3 in the range of low concentrations. Thus, as a result of the implementation of the "one pot" process, it is possible to embed oxadiazoline and oxazine cycles into the main (central) part of the compound 1 molecule, which leads to the synthesis of new drugs with antimicrobial and antifungal activity.
APA, Harvard, Vancouver, ISO, and other styles
10

Mali, Ravindra, and Javesh Patil. "Nanoparticles: A Novel Antifungal Drug Delivery System." In IOCN 2023. Basel Switzerland: MDPI, 2023. http://dx.doi.org/10.3390/iocn2023-14513.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antifungal drugs"

1

He, Dan, Hongmei Wu, Yujie Han, Min Liu, and Mao Lu. A meta-analysis of topical antifungal drugs to treat atopic dermatitis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0062.

Full text
Abstract:
Review question / Objective: Various bacteria and fungi colonize the skin surface of patients with AD. The colonized fungi mainly include Malassezia, non-Malassezia yeasts, and molds. Among them, Malassezia occupies 63%~86% of the fungal colonization community on the skin surface of AD patients. Although the relationship between the level of Malassezia on the skin surface and disease severity remains controversial, many studies have shown that the level of serum anti-Malassezia-specific immunoglobulin E (IgE) antibodies in AD patients is related to the disease severity, especially in patients with AD in the head and neck. The specific mechanism by which Malassezia causes or aggravates AD is unclear, but damage to the skin barrier in AD patients is a key component of the mechanism. The presence of Malassezia on the skin also seems to change its barrier function, resulting in more Malassezia and its antigens colonizing the skin surface area that is exposed to the immune system. This produces a large number of specific IgE antibodies and cytokines to aggravate the disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Chang, Lin Sun, Yin Liu, Hongbing Zhou, Jianguo Chen, Min She, and Yong Wang. The Efficacy of antifungal drugs combined with hormones in the treatment of allergic bronchopulmonary aspergillosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu, Shunyu, Yin Cheng, Shunzhang Lin, and Huanhai Liu. A Comparison of Antifungal Drugs and Traditional Antiseptic Medication for Otomycosis Treatment: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cheng, Jing, Hedong Han, Wenwen Kang, Zijin Cai, Ping Zhan, and Tangfeng Lv. Comparison of Antifungal Drugs in the Treatment of Invasive Pulmonary Aspergillosis: A Systematic Review and Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2023. http://dx.doi.org/10.37766/inplasy2023.8.0105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Maheshwari, E. Uma, and G. Jyothilakshmi. A STUDY OF ANTIFUNGAL SUSCEPTIBILITY TESTING AMONG NON ALBICANS CANDIDA IN PATIENTS OF VULVO VAGINAL CANDIDIASIS AT TERTIARY CARE CENTER. World Wide Journals, February 2023. http://dx.doi.org/10.36106/ijar/9605846.

Full text
Abstract:
Background &objectives: Candida species are emerging as a signicant pathogen certain species of Candida like Candida krusei are inherently resistant to azoles. In vitro susceptibility testing is essential for guiding therapy. The present study aims todetermine the antifungal susceptibility pattern ofNon albicansCandida isolates by disc diffusion and micro broth dilution method. Methods:This was a prospective study, conducted among 200 patients complaining of Vulvovaginal dischargeSpeciation was done as per standard microbiological methods. Non albicans Candida species were identied. Antifungal resistance was determined by disc diffusion method for uconazole, Voriconazole and by microbrothdilution for uconazole. Results: A total of 200 samples were collected from patients complaining of vaginal discharge . Out of them 69 were identied as Candida species , 31[44%] were C.albicans and 38 [56%] were non albicans Candida among them C.glabrata 22 (57%) , C.tropicalis 12 (31%), and 4 (10%) C.krusei. In the Interpretation and conclusion: present study, all the isolates of C. krusei 4 [10% ] tested showed resistance to uconazole by both disc diffusion and microbroth dilution methods . All isolates of C.glabrata 22 [ 57%] and C. tropicalis 12[31%] , tested were sensitive to uconazole by both disc diffusion and microbroth dilution . For voriconazole there was no resistance among all isolates tested by disc diffusion method. It is essential to perform susceptibility testing for all the Candida isolates for providing crucial information about the resistance pattern and help in choosing the appropriate antifungal drug for therapy. Disc diffusion method which is easy to perform can be utilized for day to day practice
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antifungal drugs' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography